WVP
CPRX icon

Worth Venture Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Worth Venture Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-344,702
Closed -$1.15M – 114
2020
Q4 		$1.15M Buy
344,702
+76,020
+28% +$255K 0.91% 34
2020
Q3 		$798K Buy
268,682
+55,732
+26% +$218K 0.65% 38
2020
Q2 		$983K Sell
212,950
-21,675
-9% -$97.4K 0.48% 34
2020
Q1 		$903K Buy
+234,625
New +$963K 0.56% 26

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Worth Venture Partners's CPRX Position: Q1 2021 in Review

Worth Venture Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2021, closing a stake of 344,702 shares — an estimated $1.15M sold.

Worth Venture Partners first reported a position in CPRX in Q1 2020 and held it in 4 quarters. The position peaked at $1.15M in Q4 2020. 133 funds tracked by Wall St. Rank hold CPRX as of Q1 2021.

  • Worth Venture Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 344,702 Catalyst Pharmaceutical shares in Q1 2021, an estimated $1.15M.
  • Worth Venture Partners first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 4 quarters.
  • Worth Venture Partners's Catalyst Pharmaceutical position peaked at $1.15M in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.